ASCO 2020 Prostate Cancer - Results from #40

Viewing 41-60 of 71 articles

ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

ASCO 2020: Efficacy of Enzalutamide + ADT in Metastatic Hormone-sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

ASCO 2020: Impact of Olaparib vs Physician’s Choice of New Hormonal Agent on Burden of Pain in mCRPC: PROfound

ASCO 2020: Phase III Study of Pembrolizumab plus Enzalutamide and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer: KEYNOTE-991

ASCO 2020: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Niraparib Plus Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone in Patients with Metastatic Prostate Cancer (MAGNITUDE)

ASCO 2020: Therapeutic Approaches to Protein Degradation: PROTACs and E3 Ligase Modulation

ASCO 2020: Results of the Randomized Phase II Study of Sipuleucel-T +/- Radium-223 in Men with Bone-Metastatic Castration Resistant Prostate Cancer

ASCO 2020: A Randomized Controlled Trial of Video-Education or In-Person Genetic Counseling for Men with Prostate Cancer (ProGen)

ASCO 2020: Discussant: Novel Biomarkers in Prostate Cancer: Is the Tissue the Issue?

ASCO 2020: Baseline Circulating Tumor Cell Counts as a Prognostic Marker of PSA Response and Progression in mCSPC: Results from Phase III SWOG S1216

ASCO 2020: The Role of Neoadjuvant Therapy for Patients with Localized Prostate Cancer

ASCO 2020: Androgen Deprivation: Too Little, Too Much, or Just Right?

ASCO 2020: The Comprehensive Methylation Landscape of mCRPC Identifies New Phenotypic Subtypes: Results from the West Coast Prostate Cancer Dream Team

ASCO 2020: Is PSMA Right on Target?

ASCO 2020: First-in-Human Phase 1 Study of ARV-110, an Androgen Receptor PROTAC Degrader in Patients with Metastatic Castration-Resistant Prostate Cancer Following Enzalutamide and/or Abiraterone Acetate Treatment

ASCO 2020: Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: Results of Cohort 6 of the COSMIC-021 Study

ASCO 2020: Circulating Tumor DNA Dynamics Associate with Treatment Response and Radiological Progression-Free Survival: Analyses from a Randomized Phase II Trial in Metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Radium-223 and Niraparib Treatment in Castrate-Resistant Prostate Cancer Patients with and without Prior Chemotherapy

ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone

ASCO 2020: Results from the HERO Phase III Trial Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer

1
2
3
4